CVE-2025-62575 Details
Description
NMIS/BioDose V22.02 and previous versions rely on a Microsoft SQL Server database. The SQL user account 'nmdbuser' and other created accounts by default have the sysadmin role. This can lead to remote code execution through the use of certain built-in stored procedures.
A vulnerability exists in Mirion Medical's NMIS/BioDose software versions through 22.02, due to incorrect permission assignments that grant the SQL user 'nmdbuser' and other default accounts sysadmin roles. This misconfiguration allows for remote code execution by exploiting certain built-in stored procedures. Additionally, the application's installation directory may have insecure file permissions, potentially enabling users on client workstations to modify program executables and libraries.
Users are advised to update to version 23.0 or later. Those with an active support contract can contact Mirion Medical support for assistance.
Metrics
CVSS 4.0 Severity and Vector Strings:
CVSS 3.x Severity and Vector Strings:
No data available for CVSS Version 2.0 on this CVE.
CISA-ADP
Assessed Dec 2, 2025References to Advisories, Solutions, and Tools
By selecting these links, you will be leaving this site. These are references gathered from the official CVE record and are not endorsed by Volerion.
| URL | Source(s) | Tag(s) |
|---|---|---|
| https://www.cisa.gov/news-events/ics-medical-advisories/icsma-25-336-01 | [email protected] | Third Party Advisory |
Weakness Enumeration
| CWE-ID | CWE Name | Source |
|---|---|---|
| CWE-732 | Incorrect Permission Assignment for Critical Resource | [email protected] |
Affected Products
| Product | Versions |
|---|---|
| mirion biodose/nmis | < 23.0 |
CPE
Remediation
| |
Change History
5 change records found show changes
| Date | Action | Recorded By |
|---|---|---|
| Sep 25, 2026 | CVE Translated | [email protected] |
| Jun 17, 2026 | CVE Modified | [email protected] |
| Jun 17, 2026 | CVE Modified | CISA-ADP |
| Jan 2, 2026 | Initial Analysis | [email protected] |
| Dec 2, 2025 | New CVE Received | [email protected] |